Last reviewed · How we verify

Captafer®

American University of Beirut Medical Center · FDA-approved active Small molecule

Captafer is an iron-chelating agent that binds and removes excess iron from the body to treat iron overload conditions.

Captafer is an iron-chelating agent that binds and removes excess iron from the body to treat iron overload conditions. Used for Chronic iron overload due to repeated blood transfusions (transfusional iron overload), Iron overload in patients with chronic hemolytic anemias.

At a glance

Generic nameCaptafer®
SponsorAmerican University of Beirut Medical Center
Drug classIron chelator
TargetFerric iron (Fe³⁺)
ModalitySmall molecule
Therapeutic areaHematology
PhaseFDA-approved

Mechanism of action

Captafer works by forming stable complexes with ferric iron (Fe³⁺), facilitating its excretion through urine and feces. This mechanism helps reduce iron accumulation in organs such as the heart, liver, and endocrine glands, preventing iron-related tissue damage and organ dysfunction in patients with chronic iron overload from transfusions or hemolytic anemias.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results